Literature DB >> 28629596

Attaining precision therapy in prostate cancer: A tall order.

Eleni Efstathiou1.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28629596      PMCID： PMC6051349          DOI： 10.1016/j.ejca.2017.05.011

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


× No keyword cloud information.
  13 in total

Review 1.  Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer.

Authors:  Christopher J Logothetis; Gary E Gallick; Sankar N Maity; Jeri Kim; Ana Aparicio; Eleni Efstathiou; Sue-Hwa Lin
Journal:  Cancer Discov       Date:  2013-06-28       Impact factor: 39.397

2.  Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1.

Authors:  Matthew Smith; Johann De Bono; Cora Sternberg; Sylvestre Le Moulec; Stéphane Oudard; Ugo De Giorgi; Michael Krainer; Andries Bergman; Wolfgang Hoelzer; Ronald De Wit; Martin Bögemann; Fred Saad; Giorgio Cruciani; Antoine Thiery-Vuillemin; Susan Feyerabend; Kurt Miller; Nadine Houédé; Syed Hussain; Elaine Lam; Jonathan Polikoff; Arnulf Stenzl; Paul Mainwaring; David Ramies; Colin Hessel; Aaron Weitzman; Karim Fizazi
Journal:  J Clin Oncol       Date:  2016-07-11       Impact factor: 44.544

3.  Commentary on "Integrative clinical genomics of advanced prostate cancer". Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G, Beltran H, Abida W, Bradley RK, Vinson J, Cao X, Vats P, Kunju LP, Hussain M, Feng FY, Tomlins SA, Cooney KA, Smith DC, Brennan C, Siddiqui J, Mehra R, Chen Y, Rathkopf DE, Morris MJ, Solomon SB, Durack JC, Reuter VE, Gopalan A, Gao J, Loda M, Lis RT, Bowden M, Balk SP, Gaviola G, Sougnez C, Gupta M, Yu EY, Mostaghel EA, Cheng HH, Mulcahy H, True LD, Plymate SR, Dvinge H, Ferraldeschi R, Flohr P, Miranda S, Zafeiriou Z, Tunariu N, Mateo J, Perez-Lopez R, Demichelis F, Robinson BD, Schiffman M, Nanus DM, Tagawa ST, Sigaras A, Eng KW, Elemento O, Sboner A, Heath EI, Scher HI, Pienta KJ, Kantoff P, de Bono JS, Rubin MA, Nelson PS, Garraway LA, Sawyers CL, Chinnaiyan AM.Cell. 21 May 2015;161(5):1215-1228.

Authors:  Stephen J Freedland; William J Aronson
Journal:  Urol Oncol       Date:  2017-06-13       Impact factor: 3.498

4.  Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial.

Authors:  Peter Hoskin; Oliver Sartor; Joe M O'Sullivan; Dag Clement Johannessen; Svein I Helle; John Logue; David Bottomley; Sten Nilsson; Nicholas J Vogelzang; Fang Fang; Mona Wahba; Anne-Kirsti Aksnes; Christopher Parker
Journal:  Lancet Oncol       Date:  2014-10-17       Impact factor: 41.316

5.  Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.

Authors:  Johann Sebastian de Bono; Stephane Oudard; Mustafa Ozguroglu; Steinbjørn Hansen; Jean-Pascal Machiels; Ivo Kocak; Gwenaëlle Gravis; Istvan Bodrogi; Mary J Mackenzie; Liji Shen; Martin Roessner; Sunil Gupta; A Oliver Sartor
Journal:  Lancet       Date:  2010-10-02       Impact factor: 79.321

6.  Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer.

Authors:  Tomasz M Beer; Eugene D Kwon; Charles G Drake; Karim Fizazi; Christopher Logothetis; Gwenaelle Gravis; Vinod Ganju; Jonathan Polikoff; Fred Saad; Piotr Humanski; Josep M Piulats; Pablo Gonzalez Mella; Siobhan S Ng; Dirk Jaeger; Francis X Parnis; Fabio A Franke; Javier Puente; Roman Carvajal; Lisa Sengeløv; M Brent McHenry; Arvind Varma; Alfonsus J van den Eertwegh; Winald Gerritsen
Journal:  J Clin Oncol       Date:  2016-10-31       Impact factor: 44.544

7.  Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer.

Authors:  Cora Sternberg; Andrew Armstrong; Roberto Pili; Siobhan Ng; Robert Huddart; Neeraj Agarwal; Denis Khvorostenko; Olexiy Lyulko; Arija Brize; Nicholas Vogelzang; Rémy Delva; Mihai Harza; Anastasios Thanos; Nicholas James; Patrick Werbrouck; Martin Bögemann; Thomas Hutson; Piotr Milecki; Simon Chowdhury; Enrique Gallardo; Gilberto Schwartsmann; Jean-Christophe Pouget; Frédérique Baton; Thore Nederman; Helen Tuvesson; Michael Carducci
Journal:  J Clin Oncol       Date:  2016-06-13       Impact factor: 44.544

8.  Enzalutamide in metastatic prostate cancer before chemotherapy.

Authors:  Tomasz M Beer; Andrew J Armstrong; Dana E Rathkopf; Yohann Loriot; Cora N Sternberg; Celestia S Higano; Peter Iversen; Suman Bhattacharya; Joan Carles; Simon Chowdhury; Ian D Davis; Johann S de Bono; Christopher P Evans; Karim Fizazi; Anthony M Joshua; Choung-Soo Kim; Go Kimura; Paul Mainwaring; Harry Mansbach; Kurt Miller; Sarah B Noonberg; Frank Perabo; De Phung; Fred Saad; Howard I Scher; Mary-Ellen Taplin; Peter M Venner; Bertrand Tombal
Journal:  N Engl J Med       Date:  2014-06-01       Impact factor: 91.245

9.  The Molecular Taxonomy of Primary Prostate Cancer.

Authors: 
Journal:  Cell       Date:  2015-11-05       Impact factor: 41.582

Review 10.  Galeterone for the treatment of advanced prostate cancer: the evidence to date.

Authors:  Diogo A Bastos; Emmanuel S Antonarakis
Journal:  Drug Des Devel Ther       Date:  2016-07-15       Impact factor: 4.162
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.